CAR T cell News and Research

RSS

New T cell biomarker could be much-needed patient-selection tool for CAR T cell therapy

Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia don't respond to chimeric antigen receptor T cell therapy, and the answer is tied to how primed patients' immune systems are before the therapy is administered.

30 Apr 2018

New CAR-T therapy could provide safer, more effective cancer treatment

There have been few cancer treatments with such a promising future as using the patient's own immune system.

27 Apr 2018

Gene-editing technology enhances T cell immunotherapies for treating cancer

Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient's own immune cells -- called T cells -- and supercharging them to home in on and attack specific blood cancers, such as hard-to-treat acute lymphoblastic leukemia and non-Hodgkin lymphoma.

6 Mar 2018

Antibiotic use may affect efficacy of cancer immunotherapies

Antibiotic use is known to have a near-immediate impact on our gut microbiota and long-term use may leave us drug-resistant and vulnerable to infection.

2 Mar 2018

Research shows how viruses inactivate immune system, causing cancer

It's no new news that viruses cause cancer. For example, human papillomavirus causes almost all of the more than 500,000 annual worldwide cases of cervical cancer.

2 Mar 2018

New guidelines offer recommendations for assessment, management of immunotherapy side effects

Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body's immune system to attack cancer, these treatments can send even the most hard-to-treat cancers into lasting remission.

15 Feb 2018

Scientists develop immune-stimulating injections against cancer

A team of researchers have developed two immune-stimulating injections, that removed all traces of cancer when injected directly into solid mouse tumors.

2 Feb 2018

Researchers use immune-mimicking biomaterial scaffolds to fast track T cell therapies

Immunologists and oncologists are harnessing the body's immune system to fight cancers and other diseases with adoptive cell transfer techniques. In a normal immune response, a type of white blood cell known as T cells are instructed by another kind of immune cell called an antigen-presenting cell (APC) to expand their numbers and stay alive.

15 Jan 2018

Researchers develop remote-controlled mechanogenetics system to target and kill cancer cells

A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

15 Jan 2018

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients.

11 Dec 2017

Two immunotherapy approaches for multiple myeloma show hope

Researchers from the University of Pennsylvania's Abramson Cancer Center have developed two experimental immunotherapy methods that include one chimeric antigen receptor (CAR) T cell therapy for the treatment of multiple myeloma patients who were not responding to other treatments.

11 Dec 2017

UNC Lineberger professor receives The Leukemia & Lymphoma Society grant for immunotherapy research

UNC Lineberger Comprehensive Cancer Center researcher Barbara Savoldo, MD, PhD, was awarded a $600,000, three-year grant from The Leukemia & Lymphoma Society to support research into an immunotherapy treatment being developed with a "safety switch" to safeguard against potential side effects of the treatment.

21 Nov 2017

Researchers develop new way to genetically engineer T cells for treating leukemia relapse

Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia relapse.

25 Oct 2017

Dana-Farber, Brigham and Women's Cancer Center certified to offer new CAR T-cell therapy

Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women's Hospital, the first chimeric antigen receptor (CAR) T-cell therapy for adult cancers was approved by the Food and Drug Administration today.

20 Oct 2017

New CAR-T cell therapy offers effective option for certain blood cancer patients

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers.

19 Oct 2017

Cascade of costs could push new gene therapy above $1 million per patient

Outrage over the high cost of cancer care has focused on skyrocketing drug prices, including the $475,000 price tag for the country's first gene therapy, Novartis' Kymriah, a leukemia treatment approved in August.

17 Oct 2017

Study provides detailed characterization of neurotoxicity arising from CD19 CAR T-cell therapy

New potential biomarkers and a novel algorithm could help identify patients at increased risk of suffering from severe neurotoxicity after receiving CD19 CAR T-cell therapy. The study extensively characterized common and occasionally fatal side effects of this immunotherapy.

12 Oct 2017

New gene therapy to treat cancer in children, young adults offers hopes and challenges

The first gene therapy for cancer, approved by the Food Drug Administration in August, will transform the treatment of a particular kind of cancer in children and young adults. It's transformative because it uses a patient's own immune cells to attack the cancer cells.

3 Oct 2017

UChicago Medicine working with Novartis to offer breakthrough gene therapy for pediatric ALL patients

The University of Chicago Medicine is one of a limited number of U.S. sites working to offer a breakthrough gene therapy for pediatric acute lymphoblastic leukemia (ALL), which was just approved by the U.S. Food and Drug Administration.

31 Aug 2017

FDA makes the first gene therapy Kymriah available for treatment of pediatric ALL

The U.S. Food and Drug Administration (FDA) has issued a press release making the first even gene therapy available for treatment of children with a form of acute lymphoblastic leukemia (ALL).

30 Aug 2017